Answers are grounded in this paper and cite their sources.
Central GLP-1 is a novel regulator of chylomicron production via melanocortin-4 receptors. Our findings point to the relative importance of central accessibility of GLP-1-based therapies and compel further studies examining the status of this brain-gut axis in the development of diabetic dyslipidemia and chylomicron overproduction.
No takes yet. Share an insight, caveat, or question.
Farr et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: